Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers

•Pivotal trials of COVID-19 vaccines did not include cancer patients, with questions remaining about their safety and efficacy in this population•In this cohort study we investigated the safety and efficacy of COVID-19 vaccines in 207 patients with thoracic cancer receiving anticancer treatments•After long follow-up, there were no safety signals of concern and only 0.5% of patients experienced grade 3 vaccine-related adverse events•In our cohort ∼10% of patients had a positive nasal swab after vaccination: 67% asymptomatic and 33% symptomatic (symptoms were mild)